Table 2.

Effect of Lovastatin Use on Acute Cardiovascular Events in Persons with CKD^*

Event	Placebo n(%)	Lovastatin, n(%)¶	Unadjusted RR (95% CI)	Parsimonious model RR (95% CI)†	Fully adjusted model RR (95% CI) ‡	P value
Unstable angina	6 (3.8)	3 (2.1)	0.56 (0.14–2.23)	0.58 (0.14–2.31)	0.49 (0.11–2.28)	0.4
Fatal and non-fatal MI	6 (3.8)	2 (1.4)	0.37 (0.07–1.81)	0.19 (0.04–1.01)	0.10 (0.01–1.32)	0.08
Fatal and non-fatal coronary events	18 (11.3)	7 (4.8)	0.42 (0.17–0.99)	0.29 (0.12–0.72)	0.35 (0.13–0.93)	0.03
Fatal and non-fatal CV events	21 (13.2)	8 (5.5)	0.40 (0.18–0.91)	0.31 (0.13–0.72)	0.39 (0.16–0.93)	0.03
Coronary revascularizations procedures	16 (10.1)	4(2.8)	0.26 (0.09–0.79)	0.18 (0.06–0.57)	0.23(0.07–0.77)	0.01
CHD mortality	0 (0.0)	0 (0.0)	– – –	– – –	– – –	– – –
CV mortality	1(0.6%)	0 (0.0)	– – –	– – –	– – –	– – –

^*All models were based on complete data for 304 participants with chronic kidney disease (159 in the placebo group and 145in the lovastatin group). Relative risk (RR) derived from Cox proportional hazards models.

^¶Percentages are cumulative incidences

^†Parsimonious model: age, sex, smoking, hypertension, systolic blood pressure and diabetes

^‡Fully adjusted model: age, sex, race, body mass index, smoking, family history of premature coronary artery disease, hypertension, diabetes, systolic and diastolic blood pressure, baseline glucose, total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, and use of angiotensin converting enzyme inhibitors, beta blockers, calcium channel blockers, diuretics, alpha blockers and aspirin.

p value only for fully adjusted model